as of 12-08-2025 12:25pm EST
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Learn more about our FTRE ML prediction model
Our stocks FTRE ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.
We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.
Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.
We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.
Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.
Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.
Our FTRE ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"FTRE Forecast & Prediction for December 8, 2025 Fortrea Holdings Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.